Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
- Conditions
- Interventions
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03495024
- Locations
- 🇺🇸
Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 320
- Registration Number
- NCT03262662
- Locations
- 🇺🇸
State University of New York at Buffalo, Buffalo, New York, United States
Metabolism-informed Care for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 82
- Registration Number
- NCT03227679
UW Quitting Using Intensive Treatment Study (QUITS)
- Conditions
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 1251
- Registration Number
- NCT03176784
- Locations
- 🇺🇸
UW Center for Tobacco Research and Intervention, Milwaukee, Wisconsin, United States
🇺🇸UW Center For Tobacco Research and Intervention, Madison, Wisconsin, United States
Stage Ib Trial of mSMART With Varenicline
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Duke University
- Registration Number
- NCT03069768
- Locations
- 🇺🇸
Duke Health Behavior Neuroscience Research Lab, Durham, North Carolina, United States
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 62
- Registration Number
- NCT03059563
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
Human Laboratory Study of Varenicline for Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2019-10-23
- Target Recruit Count
- 47
- Registration Number
- NCT03035708
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Brown University, Providence, Rhode Island, United States
Treating Smokeless Tobacco Use in Rural Veterans
- Conditions
- Interventions
- Behavioral: Tailored behavioral interventionBehavioral: Tobacco quit lineBehavioral: Behavioral activation for elevated depressive symptomsBehavioral: Educational materialsBehavioral: Post-cessation weight gain managementBehavioral: Alcohol use risk reductionDrug: Nicotine replacement therapy - transdermal nicotine patchDrug: Nicotine replacement therapy - nicotine lozengeDrug: Nicotine replacement therapy - nicotine gumDrug: Bupropion sustained releaseDrug: VareniclineDrug: Combination nicotine replacement therapyDrug: Combination nicotine replacement therapy + bupropion
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Mark Vander Weg
- Target Recruit Count
- 123
- Registration Number
- NCT02994082
- Locations
- 🇺🇸
Iowa City VA Healthcare System, Iowa City, Iowa, United States
Cytisine Versus Varenicline for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- University of Auckland, New Zealand
- Target Recruit Count
- 679
- Registration Number
- NCT02957786
- Locations
- 🇳🇿
National Institute for Health Innovation, University of Auckland, Auckland, North Island, New Zealand
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 25
- Registration Number
- NCT02933372
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.